Abreva enters new markets
This article was originally published in The Tan Sheet
Executive Summary
Cold sore remedy approved for OTC sale in Canada, could be available by year end under exclusive licensing agreement with GlaxoSmithKline, Avanir Pharmaceuticals says May 28. Deal with GSK, which was announced in March 2000 and also gave GSK U.S. marketing rights to Abreva, provides Avanir with royalties based on wholesale product revenue. Before GSK launches the docosanol 10% cream in Canada, firm must attain provincial approval from the national drug scheduling recommendation committee; GSK is scheduling a presentation before committee for September. Avanir also announces product approvals in Korea, Israel...